Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer
Delfina Popiel(Celon Pharma (Poland)), Jerzy Pieczykolan(Celon Pharma (Poland))
Cited by 5
Related Papers
Targeted Next-Generation Sequencing in the Diagnosis of Facial Dysostoses
|Frontiers in Genetics|2020|18
Results from Genetic Studies in Patients Affected with Craniosynostosis: Clinical and Molecular Aspects
|Frontiers in Molecular Biosciences|2022|8